159 citations
,
October 2015 in “Science Advances” This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.
25 citations
,
February 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, topical application of the SCD1 inhibitor XEN103 significantly reduced sebaceous gland size and number in mouse skin, suggesting potential local therapeutic effects for acne treatment without systemic side effects.
6 citations
,
August 2014 in “Toxicologic pathology” This study found that prolonged inhibition of DGAT1 in mice and dogs led to atrophy of sebaceous glands, with mice also experiencing alopecia, suggesting potential skin-related risks for humans using DGAT1 inhibitors.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.